IQ-AI Limited IQAI's Sponsored Phase I Clinical Trial is Open (2319E)
March 09 2022 - 10:08AM
UK Regulatory
TIDMIQAI
RNS Number : 2319E
IQ-AI Limited
09 March 2022
FOR IMMEDIATE RELEASE
IQ-AI LIMITED
("IQ-AI" or the "Company")
IQAI's Sponsored Phase I Clinical Trial is Open
Milwaukee - 9 March 2022: IQ-AI Limited (OTCQB: IQAIF) (LSE:
IQAI) is pleased to announce that the sponsored Phase I clinical
trial for oral gallium maltolate (GaM) is open for enrolment. The
trial is being led by Dr. Jennifer Connelly, MD, Associate
Professor of Neurology, and Dr. Christopher Chitambar, MD, Emeritus
Professor of Medicine and Biophysics, Division of Hematology and
Oncology, both at the Medical College of Wisconsin (MCW). Patient
recruitment in the trial is underway and potential volunteers that
meet the inclusion criteria have already been identified.
This Phase I dose escalation study is designed to determine the
optimal dose of GaM that can be administered safely. It is the
first-in-human clinical trial for an oral form of GaM to be used in
patients with high-grade brain tumours.
"I applaud the efforts of everyone involved in qualifying a new
encapsulation supplier and preparing the necessary documentation to
the FDA, and that the start of this much anticipated trial is now
finally underway," said Trevor Brown, CEO of IQAI.
The Directors of the Company accept responsibility for the
contents of this announcement
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms
part of retained EU law (as defined in the European Union
(Withdrawal) Act 2018).
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides
visualisation and analytical solutions that enable clinicians to
better diagnose and treat disease with greater confidence. Through
close collaboration with top researchers and clinicians,
sophisticated advancements are translated into platform-independent
and automated software plug-ins which can extend the base
functionality of workstations, imaging systems, PACS, or medical
viewers. By design, IB's advanced visualisation software seamlessly
integrates into routine workflows. For more information about
Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDJLMATMTMMBJT
(END) Dow Jones Newswires
March 09, 2022 10:08 ET (15:08 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Sep 2023 to Sep 2024